Germline BRCA1/2 Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis

Authors:
  • AKAleksandra Konieczna
    Aleksandra Konieczna
  • KŚKatarzyna Świderska
    Katarzyna Świderska
  • MHMiloš Holánek
    Miloš Holánek
  • RDRoman Dubiański
    Roman Dubiański
  • LRLenka Rušinová
    Lenka Rušinová
  • MPMałgorzata Pieniążek
    Małgorzata Pieniążek
  • APAnika PęKala
    Anika PęKala
  • DDDana Dvořáková
    Dana Dvořáková
  • RSRenata Soumarová
    Renata Soumarová
  • JKJoanna Kiszka
    Joanna Kiszka
  • JŻJustyna Żubrowska
    Justyna Żubrowska

Abstract
Background: Germline BRCA1/2 mutations may influence sensitivity to systemic therapy in triple-negative breast cancer (TNBC), but their association with outcomes of first-line pembrolizumab plus chemotherapy remains uncertain. This study aimed to assess the association between germline BRCA1/2 mutation status and treatment outcomes in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10 advanced TNBC receiving first-line pembrolizumab plus chemotherapy. Methods: This planned biomarker subanalysis of the retrospective, 20-centre CEBCC-101 cohort included 139 patients with documented germline BRCA1/2 status (gBRCA1/2m, n = 23; gBRCA1/2wt, n = 116). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses. Results: Patients with gBRCA1/2m were younger than those with gBRCA1/2wt (median 51.5 vs. 56.3 years; p = 0.038), with no other significant differences in assessed baseline characteristics. ORR was 78.3% versus 52.2%, respectively (p = 0.038; adjusted OR 6.172, 95% CI 1.581–24.091; p = 0.009). Median PFS was 11.1 versus 8.3 months (log-rank p = 0.181; adjusted HR 0.602, 95% CI 0.331–1.096; p = 0.097) and median OS was 26.1 versus 20.4 months (log-rank p = 0.244; adjusted HR 0.427, 95% CI 0.183–0.996; p = 0.049). No statistically significant differences in the analysed grade ≥ 2 adverse-event categories were detected. Conclusions: In this planned CEBCC-101 subanalysis, documented germline BRCA1/2 status was associated with a higher ORR during first-line pembrolizumab plus chemotherapy. Without a chemotherapy-only comparator, this association cannot be attributed specifically to pembrolizumab and may partly reflect greater sensitivity to DNA-damaging chemotherapy. No statistically significant safety differences were detected. Survival findings remain exploratory.